Peter Hess was a reporter for Spectrum from 2019 to 2023, where he covered cannabinoids, autism prevalence, social hormones and other topics. Before joining Spectrum in 2019, he was associate science editor at Inverse, where he wrote and edited stories for a broad audience on a wide range of scientific topics, including drugs, evolution and environmental science. His work has also appeared in The Washington Post, New Scientist, Popular Science and Motherboard. Peter has an M.A. in science journalism from New York University’s Science, Health and Environmental Reporting Program. Find him on Twitter at @PeterNHess.
Peter Hess
Former news writer
Spectrum
From this contributor
Capturing autism’s sleep problems with devices nearable and wearable
Next-generation trackers could realize a long-standing research dream: conducting sleep studies in large numbers of autistic people.
Capturing autism’s sleep problems with devices nearable and wearable
By
Angie Voyles Askham, Peter Hess
6 June 2023 | 5 min read
Going on Trial: Epidiolex for autism; arbaclofen tests; pain monitoring
This month’s issue of Going on Trial takes a sneak peek at some early null results from a small trial of a cannabidiol-based drug for autism, among other recent drug developments.
Going on Trial: Epidiolex for autism; arbaclofen tests; pain monitoring
By
Peter Hess
30 May 2023 | 7 min read
Swings and misses with Jeremy Veenstra-VanderWeele
A careful clinician who prizes evidence, Jeremy Veenstra-VanderWeele is happy to embrace trial failures, as long as he learns from them.
Ruth Carper: Imaging the aging brain in autistic adults
Few studies have tracked how brain structure and function change across adulthood in people with autism. Carper and her colleagues are collecting data to fill this gap.
Ruth Carper: Imaging the aging brain in autistic adults
By
Peter Hess
19 May 2023 | 7 min read
Autism-related genes converge on microglia and dopamine in zebrafish
The findings add to the growing evidence that genes with disparate functions can play similar roles in brain development.
Autism-related genes converge on microglia and dopamine in zebrafish
By
Peter Hess
12 May 2023 | 4 min read
Explore more from The Transmitter
Autism scientists push back on CDC’s inaccurate vaccine claims
The CDC website now falsely suggests that autism-vaccine research is still an open question, prompting distrust among researchers—some of whom anticipate “more unreliable statements coming from the junta that took over” the agency.
Autism scientists push back on CDC’s inaccurate vaccine claims
The CDC website now falsely suggests that autism-vaccine research is still an open question, prompting distrust among researchers—some of whom anticipate “more unreliable statements coming from the junta that took over” the agency.
By
The Transmitter
21 November 2025 | 6 min read
Gene replacement therapy normalizes some traits in SYNGAP1 model mice
The first published virus-based gene therapy for SYNGAP1 deletion yields benefits despite the gene’s long length and complexity.
Gene replacement therapy normalizes some traits in SYNGAP1 model mice
The first published virus-based gene therapy for SYNGAP1 deletion yields benefits despite the gene’s long length and complexity.
By
Charles Q. Choi
20 November 2025 | 5 min read
Does AI understand what it produces? Henk de Regt explores how we might assess understanding in machines and humans
Building on his philosophy of how scientists understand what they work on, de Regt is extending his approach to test understanding in machines.
Does AI understand what it produces? Henk de Regt explores how we might assess understanding in machines and humans
Building on his philosophy of how scientists understand what they work on, de Regt is extending his approach to test understanding in machines.
By
Paul Middlebrooks
19 November 2025 | 1 min read